News

John Theurer Cancer Center Researcher Recognized for Innovation in Multiple Myeloma

Thu, October 17, 2013

John Theurer Cancer Center researcher, Dr. Jenny Zilberberg, Ph.D., will be recognized for her research in multiple myeloma on the evening of October 17th, 2013, receiving a 2013 Innovator Award from the Steven’s Institute of Technology. The Award honors inventors, organizations, and others who have contributed to innovation in New Jersey, the Invention State. Dr. Zilberberg’s research focused on an ex vivo method to determine the effectiveness of personalized treatment strategies for multiple myeloma cancers. Click here to read more about the award.

Beyond Kyprolis And Pomalyst: What Is Next On The Horizon?

Tue, April 23, 2013

Within the past nine months, two new agents have been approved for the treat­ment of relapsed multiple myeloma.

In July 2012, a second generation proteasome inhibitor, Kyprolis (car­filzomib), was approved for patients with relapsed/refractory disease. In February of this year, Pomalyst (pomalidomide) was approved for use in similar patients.           Click here to read more

Challenges of a Young Adult with Cancer

Fri, January 04, 2013

Student loans and cancer don't go well together - one of the many issues young adults face and we'll be discussing. NBC New York helps JTCC patient navigate Jonathan Viaud the system. Click here to watch the news video.

Pomalidomide (Celgene) is the next new drug for multiple myeloma, expected to be approved early in 2013.

Sun, December 09, 2012

ATLANTA, Georgia— Pomalidomide (Celgene) is the next new drug for multiple myeloma, expected to be approved early in 2013.

An immunomodulatory drug from the same stable as thalidomide ( Thalomid, Celgene) and lenalidomide ( Revlimid, Celgene), this new drug "is the most active by far," says David Siegel, MD, PhD, chief of multiple myeloma at the John Theurer Cancer Center at Hackensack University Medical Center, in New Jersey. Click here to read more.

An investigational drug for multiple myeloma, the first oral proteasome inhibitor, has shown promising results in an early phase

Sun, December 09, 2012

ATLANTA, Georgia — An investigational drug for multiple myeloma, the first oral proteasome inhibitor, has shown promising results in an early phase1/2 clinical trial and has progressed straight into phase 3 clinical trials. If all goes well, it is predicted to reach the market in 2014.

Currently known only as MLN9708 (Millennium), this new drug is taken orally once weekly and will offer an alternative to bortezomib ( Velcade, Millennium), the first proteosome inhibitor developed for multiple myeloma, which is now commonly used in the treatment of this disease. Click here to read more.

Researchers Publish Final Results Of Kyprolis Study That Led To FDA Approval

Mon, August 06, 2012

Final results from a Phase 2 study show that Kyprolis can be an effective treatment for relapsed and refractory multiple myeloma patients, with nearly a quarter of these patients responding to treatment.

Dr. David Siegel, lead investigator from John Theurer Cancer Center and lead investigator of the study, said the results demonstrate that Kyprolis (carfilzomib) has “excellent activity with low toxicity.” Click here to read more.

Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma

Thu, August 02, 2012

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib (Kyprolis) would be a safe and effective alternative to bortezomib (Velcade) for the treatment of multiple myeloma.

“This study strengthens the conclusion that carfilzomib has significant activity in patients who have no remaining treatment options, and thus have a critically important unmet need,” according to lead author David Siegel, MD, PhD, John Theurer Cancer Center, Hackensack, New Jersey. Click here to read more.

US grants accelerated approval for Onyx’ Kyprolis

Mon, July 23, 2012

The US Food and Drug Administration gave the thumbs up for Kyprolis (carfilzomib) to treat patients with multiple myeloma whose disease has progressed despite having had at least two prior therapies, including bortezomib and an immunomodulatory agent. John Theurer Cancer Center's Dr. Siegel was the lead investigator in the study. Click here to read more.

FDA OKs Kyprolis for Myeloma

Fri, July 20, 2012

The FDA has approved the proteasome inhibitor carfilzomib (Kyprolis) for patients with previously treated multiple myeloma.

"This approval provides a new treatment option for the significant unmet need that exists in patients with multiple myeloma who have progressed after use of available treatments," David Siegel, MD, of Hackensack University Medical Center in New Jersey, said in the statement from Onyx. Click here to read more.

Sunscreen labels to get stricter, but not this summer

Thu, May 31, 2012

As the weather gets warmer, enjoying the sunshine becomes top priority. But increased sun exposure also means an increased risk of sunburn and, in turn, skin cancer if you don't adequately protect yourself. Dr. Robin Ashinoff, chief of dermatologic and cosmetic surgery at Hackensack University Medical Center, comments on the importance of protecting yourself during the summer heat. Click here to read more. 

Free head, neck and oral screenings being offered at Hackensack University Medical Center

Tue, April 17, 2012

NorthJersey.com talks about John Theurer Cancer Center's partnership with the Head and Neck Cancer Alliance in offering free oral, head, and neck cancer screenings. Click here to read more.

The Link Between Nutrition And Breast Cancer

Tue, March 27, 2012

Great article from the Dierdre Imus Foundation about how good nutrition can be a valuable ally in the fight against breast cancer. Click here to read more.

OncLive: What Patients Don’t Know Might Hurt Them

Mon, March 26, 2012

Dr. Andrew Pecora comments on the effects of complimentary and alternative medicines. Click here to read more. 

Myeloma Beacon: The Top Myeloma Research of 2011

Fri, March 09, 2012

David Vesole, M.D., Co-Chief, Multiple Myeloma weighs in on the top myeloma research of 2011. John Theurer Cancer Center researchers were involved in the most promising study of 2011, sequencing of the multiple myeloma genome, and are now building on this landmark study with the Multiple Myeloma Research Foundation. Click here to read more.

OncLive: John Theurer Cancer Center - Providing Extraordinary Care to the Community

Tue, February 14, 2012

Year after year, John Theurer Cancer Center harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.  Click here to read about the research and innovations being conducted here. 

Myeloma Beacon: Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011)

Mon, January 23, 2012

David Vesole, M.D., Ph.D., F.A.C.P, Co-Chief and Director of Research, Multiple Myeloma Division, John Theurer Cancer Center, discusses the effectiveness of marizomib in treating relapsed/refractory myeloma as it relates to the study abstract presented at the American Society of Hematology (ASH) annual meeting in San Diego last month. Click Here to read the article.

ManagingMyeloma: David Siegel, M.D., Ph.D, Co-Chief, Myeloma, Discusses Treatment Goals When Managing Relapsed/Refractory MM

Fri, January 06, 2012

David Siegel, M.D., Ph.D, Co-Chief, Multiple Myeloma Division, John Theurer Cancer Center at Hackensack University Medical Center, discusses treatment goals when managing relapsed or refractory multiple myeloma in this video response.  Click here to watch.

Oncology Times: Is Maintenance Therapy Needed for Myeloma?

Sun, December 25, 2011

Maintenance therapy in multiple myeloma has been under investigation for more than three decades, without evidence of clear benefit until recently.  David Vesole, M.D., Ph.D, F.A.C.P., Co-Chief and Director of Research, Multiple Myeloma Division, John Theurer Cancer Center, offers his take on the need for maintenance therapy in treating multiple myeloma.  Click here to read the full article.

PrimeOncology: David Siegel, M.D., Ph.D., Co-Chief, Myeloma, Discusses Results from Key Abstract Presentation

Sun, December 18, 2011

Lead author David Siegel, M.D., Ph.D, Co-Chief, Multiple Myeloma Division, John Theurer Cancer Center at Hackensack University Medical Center, discussed results From  a key ASH 2011 Abstract 480 - Vantage 095: An international, multicenter, open-label study of Vorinostat (MK-0683) in combination with Bortezomib in patients with relapsed or refractory multiple myeloma.  

OncLive: Dr. Feldman Discusses Using Doxil for CTCL

Sat, December 17, 2011

Tatyana Feldman, M.D., a hematologist and oncologist specializing in lymphoma at the John Theurer Cancer Center at Hackensack University Medical Center, discusses the phase II multicenter trial examining the introduction of pegylated liposomal doxorubicin (PLD) followed by bexarotene for patients with advanced cutaneous T-cell lymphoma (CTCL).  Watch the video interview below.

 

OncUView: Tatyana Feldman, M.D., John Theurer Cancer Center, Discusses Brentoximab Vedotin in T-cell Lymphoma

Sat, December 17, 2011

From ASH 2011 - Tatyana Feldman, M.D., Hematologist/Oncologist, Lymphoma Division at the John Theurer Cancer Center, discusses Brentoximab Vedotin in T-cell Lymphoma during an interview.  Click here to watch the video.

OncUView: David H. Vesole, MD, PhD, Co-Chief, Myeloma Division, JTCC, Interviewed On Myeloma Trial Results From ASH2011

Sat, December 17, 2011

From ASH 2011 - David H. Vesole, MD, PhD, Co-Chief, Myeloma Division Director, Myeloma Research at the John Theurer Cancer Center at the Hackensack University Medical Center, discusses the final results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-dose Dexamethasone (CRd) in Multiple Myeloma, as well as the Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma.  Click here to watch the video.

OncUView: Ash 2011 Interview with K. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center

Sat, December 17, 2011

From ASH 2011 - K. Stephen Suh, Ph.D., Director of Genomics and Biomarkers Program at the John Theurer Cancer Center at the Hackensack University Medical Center, discusses personalized medicine, genomics and biomarkers during an interview.  Click here to watch the video.

ManagingMyeloma: David H. Vesole, MD, PhD, FACP, Co-Chief, Myeloma, Discusses Sequencing Therapy for Relapsed/Refractory MM

Sat, December 17, 2011

David H. Vesole, M.D., Ph.D., F.A.C.P., Co-Chief, Director of Research, Multiple Myeloma Division, discusses how therapy should be sequenced for patients with relapsed or refractory multiple myeloma.  Click here to watch the video response. 

Medpage Today: ASH: Bendamustine Shows Promise in Multiple Myeloma

Thu, December 15, 2011

David Vesole, M.D., Ph.D, F.A.C.P., Co-Chief and Director of Research, Multiple Myeloma Division, shared his thoughts from his involvement in the ASH 2011 abstract which showed that when combined with bortezomib (Velcade), bendamustine, an older alkylating drug developed behind the Iron Curtain, appears to produce responses in difficult-to-treat multiple myeloma patients.  Click here to read the article.

HemOnc Today: Triple Combination Therapy Triggered Systemic Antitumor Response in Metastatic Lymphoma

Thu, December 15, 2011

Referencing the abstract presented at the 2011 annual ASH meeting in San Diego, CA, Andre Goy, M.D., M.S., Chairman and Director, John Theurer Cancer Center, Chief, Lymphoma Division, shares his perspective on the triple combination therapy injection of low doses of anti-CTLA4 and anti-OX40, along with the toll-like receptor 9 agonist CpG, triggering a systemic antitumor response in metastatic lymphoma.  Click here to read the article.

Medpage Today: ASH: Sclerostin Levels Elevated in Multiple Myeloma

Wed, December 14, 2011

High levels of the osteocyte-secreted protein sclerostin are found in patients with multiple myeloma and that finding could give scientists a therapeutic target, researchers said here.  David Vesole, M.D., Ph.D, F.A.C.P., Co-Chief and Director of Research, Multiple Meloma Division, John Theurer Cancer Center, comments on the promising nature of these findings.  Click here to read the article.

Medscape: Vorinostat Shows Activity as Salvage in Multiple Myeloma

Wed, December 14, 2011

David Siegel, M.D., Ph.D., Co-Chief, Myeloma Division, shares his thoughts on the ASH 2011 abstract which showed the drug vorinostate to be a possible treatment in relapsed/refractory multiple myeloma.  Click here to read more. 

Prime Oncology: Virtual Poster Session Updates on Myeloma

Tue, December 13, 2011

David Siegel, M.D., Ph.D, Co-Chief, Multiple Myeloma Division, John Theurer Cancer Center, presents Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global phase 2b trial presented at ASH 2011. 

Medscape: Bortezomib Upfront in Myeloma, Survival Advantage Confirmed

Tue, December 13, 2011

David Siegel, M.D., Ph.D., Co-Chief, Myeloma Division, shares his thoughts on his ASH 2011 abstract revealing that the addition of bortezomib to standard treatment with melphalan and prednisone (MP) significantly improved overall survival.  Click here to read the article.

Medscape: New Insight Into Drug Action in Multiple Myeloma

Mon, December 12, 2011

David Siegel, M.D., Ph.D, Co-Chief, Multiple Myeloma Division, speaks on his findings regarding the discovery of the protein cereblon, to explain how Thalidomine and lenalidomide have proven highly effective in the treatment of multiple myeloma.  Click here to read the article.

John Theurer Cancer Center Named a Blue Distinction Center for Transplants

Thu, December 08, 2011

Horizon Blue Cross Blue Shield of New Jersey is pleased to announce that the John Theurer Cancer Center at Hackensack University Medical Center has been named a Blue Distinction Center for Transplants.  It is the only cancer center with such a designation in New Jersey. To read the full article, click here and view page 16.  

OncLive: Channeling His Creativity Into Oncology: A “Renaissance Man” Makes a Mark in Lymphoma Research

Thu, December 08, 2011

A physician who treats lymphoma patients at New Jersey’s largest cancer center, Dr. Andre Goy, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib, a proteasome inhibitor, in mantle cell lymphoma. To read the full profile of Dr. Goy, click here.

International Myeloma Foundation: orinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study

Wed, December 07, 2011

Lead author Dr. David Siegel, M.D., PhD, Chief, Multiple Myeloma , speaks about his clinical trial abstract presentation for "Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial" presented at the American Society of Hematology (ASH) 2011.

 

October 2011: Nurse Perspectives on Developments in Cancer Care

Fri, December 02, 2011

Colleen Masterson, RN, BSN, John Theurer Cancer Center offers her perspective on "HPV Vaccination Gaps" and Laura Metcalfe, MSN, RN, APN C, AOCNS, John Theurer Cancer Center, discusses "Benefits of a Prudent Diet."  Click here to read the article. 

Caucus: New Jersey with Steve Adubato: Personalized Medicine

Thu, December 01, 2011

Andre Goy, M.D., M.S., Chairman and Director and Chief, Division of Lymphom, discusses the role of genetics in cancer, focusing in on advancing personalized medicine.

 

FutureMedicine: Landmark Study and Novel Technology Encourage Advancement in Personalized Multiple Myeloma Treatment

Tue, November 01, 2011

Enrollment of multiple myeloma (MM) patients for a landmark study has been initiated at the John Theurer Cancer Center at Hackensack Univeristy Medical Center (NY, USA) in an initiative to further understand the genetic variation of the disease. To read the full article, click here.

Living With Multiple Myeloma: Nurses as the Lifeline

Fri, October 07, 2011

In 2001, Doug Rickert, a 46-year-old industrial management consultant and married father of 3, heard the life-altering words, “softball-sized tumor pressing against your spinal canal.”  Living with Multiple Myeloma, Doug tells his story and explains how the nurses at the John Theurer Cancer Center have been a lifeline.  Click here to read the full article.

The Record: Cancer Center Holds Party for Patients, Caregivers

Sun, September 18, 2011

The John Theurer Cancer Center at Hackensack University Medical Center, one of the top 50 cancer treatment centers in the country, put on their third annual Celebrating Life and Liberty Event for over 2,200 patients and caregivers Sunday on the lawn at Liberty State Park in Jersey City.  Click here to read article.

OncNurse: Oncology Nutritionists: Should Cancer Care Teams Include Dietary Experts?

Fri, September 16, 2011

One institution that has integrated oncology nutritionists into its treatment program is the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey.  Click here to read full article.

The Record: New Jersey hospitals conducting hundreds of clinical trials

Sat, August 20, 2011

The Record reports that hundreds of clinical trials are being conducted at New Jersey medical centers such as the John Theurer Cancer Center at Hackensack University Medical Center.  Dr. Andrew Pecora, Chief Innovations Officer and Professor and Vice President of Cancer Services at JTCC is quoted.  Click here to read the full article.

The Luxury Spot: Inspirational Makeovers for Cancer Survivors. A Touching Sunday Afternoon

Sat, August 06, 2011

The Luxury Spot reports on the Celebration of Life event organized by salon owner and celeb stylist Adrian De Berardinis in collaboration with John Theurer Cancer Center and NYC’s Gilda’s Club. A group of very special ladies added a little glamour to their normal Sunday routine. Click here to read the complete blog post and see beautiful pictures of these lovely ladies. 

The Angels of Hope Foundation Raffles Custom Chopper to Benefit Women’s Health Services at the John Theurer Cancer Center

Mon, August 01, 2011

The Angels of Hope Foundation is hosting a Chopper Raffle to benefit women’s health services at the John Theurer Cancer Center. Raffle tickets are $100 for a chance to win a custom built Chopper by the world famous Orange County Choppers with 100 percent of the proceeds benefiting women’s health. The Angels of Hope Foundation will display the Chopper at Riverside Square Mall in Hackensack, NJ on Saturday, August 20th from 10am-8pm. Tickets for the Chopper Raffle are also available for purchase at online at http://aoh-nj.org/raffle_tickets.html.

John Theurer Cancer Center Expands Multiple Myeloma Division with Specialist Dr. Joshua Richter

Thu, July 28, 2011

John Theurer Cancer Center at Hackensack University Medical Center is pleased to announce the addition of multiple myeloma specialist Joshua Richter, M.D. This appointment allows the Multiple Myeloma division to further expand its internationally-recognized myeloma clinical and research practice.

CNN Health: Fish Oil Linked to Lower Breast Cancer Risk

Fri, July 08, 2011

David Pearlstone, MD, Co-Chief, Breast Oncology, The John Theurer Cancer Center offers insight on the benefits of fish oil in preventing breast cancer.  Click here to read the full article.

CBS Evening News: Will FDA Withdraw Avastin for Breast Cancer?

Tue, June 28, 2011

CBS Evening News speaks with Dr. Waintraub and one of his patients regarding the FDA hearing on breast cancer drug Avastin.  Click here to watch the full news segment. 

WABC-TV: Get Checked: Prostate Cancer Awareness Testing

Tue, June 14, 2011

WABC-TV reports that the John Theurer Cancer Center at Hackensack University Medical Center will host free prostate cancer awareness testing on Sunday, June 18 from noon - 4pm outside of the Intrepid Sea, Air & Space Museum on the west side of Manhattan.  Participants will have an opportunity to meet former New York Knicks star guard Earl "the Pearl" Monroe.  Click here to read the full article.

MedPage Today: ASCO: Novel Agent Works for Relapsed Multiple Myeloma

Fri, June 10, 2011

MedPage Today covers results from Dr. David Siegel's clinical trial on bortezomib in patients with multiple myeloma, as presented at ASCO 2011.  Click here to read the full article.

The Record: Rooftop garden offers cancer patients respite from treatment at Hackensack University Me

Tue, June 07, 2011

The Record recently visited our unique rooftop garden for pateints.  Read the full article here, featuring commentary from Dr. Pecora and a special video tour with Dr. Goy.

NY1: HUMC Holds Free Skin Cancer Screenings

Thu, June 02, 2011

NY1 covered the John Theurer Cancer Center and the Promise Foundation's Make a Promise for Extraordinary Skin Care event.  The segment features commentary from Donald McCain, MD, PhD, Vice Chairman and Co-Chief of Gastrointestinal Oncology at JTCC.  Click here to view the full news segment.

OncLive: Beyond Broccoli: Cancer Focus Is on Food at Molecular Levels

Wed, May 25, 2011

OncLive reports on the important role that food and nutrients play in fighting cancer. Robin McConnell, MS, RD, Clinical Nutrition Coordinator at the John Theurer Cancer Center comments on the nutritional challenges that face patients at all stages of treatment and recovery.  Click here to read the full article.

Oncology Business Review: John Theurer Cancer Center: Taking Multidisciplinary Care to a New Level

Wed, May 25, 2011

The John Theurer Cancer Center's new comprehensive cancer care facility is the feature story of the May issue of Oncology Business Review.  The four-page feature highlights how JTCC is taking multidisciplinary care to a new level and features commentary from Drs. Pecora, Goy and FeldmanClick here to read the full feature.

A to Z Sensors: Wireless Radiation Sensor Implant Senses Radiation Delivered to Tumors

Wed, May 18, 2011

Article reports that the John Theurer Cancer Center is among the two cancer centers located in the tri-state region to implant a wireless radiation sensor that enables radiation oncologists to immediately receive post prostate cancer treatment data related to the exact quantity of radiation received by the tumors along with the tissue surrounding these tumors. Click here to read the complete article.

Health Data Management: App Checks Radiation Post-Treatment

Wed, May 18, 2011

Article reports that the John Theurer Cancer Center is using an implantable, wireless radiation sensor to immediately measure after treatment the amount of radiation delivered to tumors and surrounding tissue for treatment of prostate cancer. Click here to read the complete article

NY1: HUMC Cancer Center Adds New Cooking Facility

Mon, April 18, 2011

NY1 covered JTCC's Cooking Studio Shower Event.  The Cooking Studio will be used to provide patients and their caregivers with demonstrations on how to lead healthier lifestyles.  Click here to view the news segment. 

OncNurse: Nurse’s Insight: An Interview with JTCC Advanced Practice Nurse Laura Metcalfe

Thu, April 14, 2011

Intellisphere publication OncNurse features an interview with JTCC's Laura Metcalfe, MSN, RN, APN, C, AOCNS.  Mrs. Metcalfe provides insight on gastrointestinal cancer and general cancer-related topics.  Click here to read the full interview.

The Record: New drug approved for battle against melanoma

Tue, April 05, 2011

A new drug shown to prolong the lives of melanoma patients and tested in a clinical trial at JTCC has been approved for use by the FDA.  Dr. Andrew Pecora, Chief Innovations Officer and Professor and Vice President of Cancer Services at JTCC is quoted for his involvment with the clinical trial.  Click here to read the full article.

The Myeloma Beacon: Beacon NewsFlashes: MMRF Patient Seminar on Clinical Insights to be Held in Short Hills, NJ

Mon, March 28, 2011

The Myeloma Beacon reports on the MMRF Patient Seminar that will be hosted by Drs. Siegel and Vesole of the Cancer Center on Saturday, April 2 in Short Hills, NJ.  Click here to read the full newsflash.

Medscape Oncology: Multiple Myeloma Genome Sequenced, Reveals New Therapeutic Targets

Fri, March 25, 2011

Medscape Oncology covered a study co-authored by JTCC's Dr. Siegel that sequences the multiple myeloma genome.  The article features quotes from Dr. Siegel.  Click here to read the full article.

Fox News: Holistic Healing

Thu, March 24, 2011

Dr. Andrew Pecora, Chief Innovations Officer and Professor and Vice President of Cancer Services gives Fox News a tour of JTCC's new "total patient cancer care" facility.  Watch the full segment here.

El País, Uruguay: Científicos consiguen develar el genoma del mieloma multiple

Wed, March 23, 2011

El País, a major national newspaper in Uruguay reports on a study published in Nature that completes sequencing of the multiple myeloma genome.  Dr. Siegel, Chief of Multiple Myeloma at JTCC is quoted.  Click here to read the full article. 

The Myeloma Beacon: Genome Sequencing Reveals Clues About the Underlying Causes of Multiple Myeloma

Wed, March 23, 2011

The Myeloma Beacon reports on a study published in Nature that sequences the first complete multiple myeloma genome.  Dr. David Siegel, Chief of Multiple Myeloma at the John Theurer Cancer Center, one of the study's authors is quoted.  Click here to read the full article.

HemOnc Today: Researchers complete sequencing of multiple myeloma genome

Wed, March 23, 2011

HemOnc Today quotes Dr. David Siegel, Chief of Multiple Myeloma at JTCC for his involvement in a landmark study that completes sequencing of the multiple myeloma genome.  Click here to read the full article.

U.S. News & World Report: Health Day: Genome Map of Multiple Myeloma Offers Clues to Its Cause

Wed, March 23, 2011

The genome for multiple myeloma has been mapped by a team of North American scientists, which includes Dr. David Siegel, Chief of Myeloma at JTCC, who is quoted.  According to the team, this achievement will improve understanding of what causes the disease and may lead to new treatments.  Click here to read the full article.

The Star-Ledger: Hackensack University scientists catalogue, study DNA of deadly bone marrow cancer

Wed, March 23, 2011

The Star-Ledger reports on Dr. Siegel and his team's invololvement in a breakthrough study that sequences the multiple myeloma genome.  Read the full article here.

ACCC Oncology Issues: The John Theurer Cancer Center at Hackensack University Medical Center: Exceptional Design in the Service

Fri, March 18, 2011

Oncology Issues, the official publication of the Association of Community Cancer Centers (ACCC), profiles the John Theurer Cancer Center at HUMC's new cancer treatment facility in its latest issue.  Click here to read more.

OncLive: Announcnig a New Partnership and an Opportunity for Growth

Wed, March 16, 2011

JTCC's Dr. Andrew Pecora, Chief Innovations Officer and Professor and VP of Cancer Services announces partnership with Intellisphere's Oncology Specialty Group, OncLive, and his new position as editor-in-chief of Oncology & Biotech News.  Read the full article here.

Shedding More Light on Identifying HER2

Fri, March 04, 2011

John Theurer Cancer Center — The center’s Breast Cancer Division hosted the Eighth Annual Northern New Jersey Breast Cancer Conference on February 18, with leading researchers discussing major trends and studies.

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from human epidermal growth factor receptor 2 (HER2)-targeted treatment.  To read the full article, click here.

The Record: Bikers get health check pit stop at dealership

Sun, February 13, 2011

The Record reports that Prostate Net held a health awarness event at the Bergen County Harley-Davidson showroom dubbed "Ladies and Gentlemen, Check Your Engines".  Dr. Richard A. Watson, Urologist, John Theurer Cancer Center and Dr. David Pearlstone, Co-Chief of Breast Oncology, John Theurer Cancer Center were onsite to provide attendees with educational information on breast cancer and prostate cancer prevention.  Click here to read the full article.

NY1: Harley Davidson Dealership Revs Up Prostate Cancer Awareness

Sat, February 12, 2011

NY1 reports on the "Ladies and Gentlemen, Check Your Engines" health awareness event that took place at the Bergen County Harley-Davidson showroom.  The news clip features commentary from Dr. Richard Watson, urologist at the John Theurer Cancer Center.  Click here to watch the full segment.

Oncology & Biotech News: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients

Tue, February 08, 2011

Oncology & Biotech News features John Theurer Cancer Center's David Siegel, MD PhD in its ASH Recap segement following Siegel's multiple myeloma research presentation at the 52nd Annual ASH Conference. Click here to read the full article.

Wyckoff Patch: Angels of Hope: Fighting the Fear of Cancer

Thu, February 03, 2011

The Wyckoff Patch posted an article profiling the Angels of Hope Foundation.  Lynn White, the Foundation's founder and JTCC's  Dr. Andrew Pecora are quoted.  Click here to read the full article.

The Record: ‘Angels’ to Hold Annual Run/Walk

Thu, February 03, 2011

The Record reports that the Angels of Hope Foundation will hold its Sixth Annual 5K Run/Walk at 10 a.m. on Sunday,  April 17, 2011at McBride Field in Franklin Lakes.  You may read the full article here.

Oncology Issues: A Candid Conversation About CML

Tue, February 01, 2011

Oncology Issues interviews John Theruer CancerCenter’s Stuart Goldberg, MD about chronic myeloid leukemia in its latest issue. Click here to read the full article.

The Myeloma Beacon: Beacon News Flashes

Mon, January 24, 2011

John Theurer Cancer Center's Thea Friedman, MD is featured in The Myeloma Beacon for receiving a $2M grant from the National Institutes of Health and National Cancer Institute to support her myeloma research over the next five years. Click here to read the full article.

The ASCO Post: Promising Data Reported on Hematology Drugs in the Pipeline

Sat, January 15, 2011

The ASCO POST talks with John Theurer Cancer Center’s David S. Siegel, M.D. in regards to promising new data in the area on hematology drugs. To read the full article click here

Everyday Health: The High Cost of Leukemia Treatment

Thu, January 13, 2011

Anita Vargas, oncology social worker at the John Theurer Cancer Center shares tips on managing leukemia treatment costs with EverdayHealth.com.  Sharon Lee Parker, cancer coach at JTCC also provides commentary.  Click here to read the full article.

EverydayHealth.com: Telling Others You Have Leukemia

Thu, January 13, 2011

Anita Vargas, oncology social worker at the John Theurer Cancer Center provides advice on how to tell family and friends you've been diagnosed with leukemia.  Sharon Lee Parker, cancer coach at JTCC also provides commentary.  You may read the full article here.

Oncology Times: Online First: ASH Annual Meeting: Inotuzumab Ozogamicin Shows Activity in Lymphomas Both Alone & Combined with R

Mon, January 10, 2011

Oncology Times posted an "online first" article that features studies from ASH 2010 presented by JTCC's Dr. Andre GoyClick here to read the full article.

Fox News: Can stem cells help Dick Cheney?

Wed, January 05, 2011

Dr. Andrew Pecora of the John Theurer Cancer Center spoke with FoxNews regarding the use of stem cell transplantation to help treat patients with cardiovascular disease.  Read the full article here.

CancerNetwork.com: New Jersey cancer center features green lobby

Thu, December 30, 2010

CancerNetwork.com highlights the opening of the John Theurer Cancer Center's new building.  Read the news brief here.

Dr. Siegel - Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A

Tue, December 28, 2010

Dr. David Siegel, Co-Chief, Multiple Myeloma Division at the John Theurer Cancer Center discusses his presentation from the annual meeting of the American Society of Hematology (ASH) 2010.  Click here to watch the full video.  

International Myeloma Foundation: Dr. Vesole - Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival

Tue, December 28, 2010

Dr. Vesole, Co-Chief of Multiple Myeloma Division and Chief of Multiple Myeloma Research at the John Theurer Cancer Center discusses a multiple myeloma study at ASH 2010.  Watch the video here.

International Myeloma Foundation: Results of Phase 2 Study on Carfilzomib in Patients with Relapsed and Refractory Multiple Myel

Tue, December 28, 2010

Dr. David Siegel, Co-Chief of Multiple Myeloma at the John Theurer Cancer Center provides commentary on a clinical trial on the multiple myeloma drug Carfilzomib, as presented at the annual meeting of the American Society of Hematology (ASH) 2010.  Watch the video here.

International Myeloma Foundation: Results of Phase 2 Study on Carfilzomib in Patients with Relapsed and Refractory Multiple Myel

Tue, December 28, 2010

Dr. David Siegel, Co-Chief of Multiple Myeloma at the John Theurer Cancer Center provides commentary on a clinical trial on the multiple myeloma drug Carfilzomib, as presented at the annual meeting of the American Society of Hematology (ASH) 2010.  Watch the video here.

The Myeloma Beacon: Carfilzomib shows promise in both newly diagnosed and relapsed/refractory multiple myeloma patients (ASH 201

Mon, December 20, 2010

The Myeloma Beacon reports on a study on the multiple myeloma drug Carfilzomib that Dr. David Siegel of the John Theurer Cancer Center was involved with.  Click here to read the full article.  

The Myeloma Beacon: Early stem cell transplantation may improve survival in newly diagnosed multiple myeloma patients (ASH 2010)

Fri, December 17, 2010

The Myeloma Beacon highlights research from Dr. David Siegel of the John Theurer Cancer Center that examines early stem cell transplantation for patients with multiple myeloma.  Click here to read the full article

Oncology Net Guide: Focusing on the Future

Thu, December 16, 2010

Oncology Net Guide features commentary from Donna McNamara, M.D. discussing fertility treatment options for male patients and the unique challenges in fertility preservation for female patients. Click here to read the full article. 

PatientPower.Info: Dr. David Siegel reunites with patient Jack Aiello at major hematology research meeting

Thu, December 16, 2010

Dr. David Siegel of the John Theurer Cancer Center reunites with patient, 16-year multiple myeloma survivor Jack Aiello. Watch the full video here.  

PatientPower.Info: Breakthrough armed antibody offers new hope for hard to treat non-Hodgkin’s lymphoma

Thu, December 16, 2010

PatientPower.Info caught up with the John Theurer Cancer Center's Dr. Andre Goy to discuss a non-Hodgkin's lymphoma study he was involved with.  Click here to watch the video.

Science Daily: Drug combination shows promise for newly diagnosed blood cancer patients, study finds

Sat, December 11, 2010

Science Daily reports on a study for patients with myeloma that Dr. David Vesole, Co-Chief of Multiple Myeloma, Chief of Multiple Myeloma Research, the John Theurer Cancer Center was involved with.  Click here to read the full article.  

Medpage Today: ASH: Secondary Cancers Cloud Myeloma Drug

Thu, December 09, 2010

Medpage Today quotes Dr. David Siegel and Dr. David Vesole for their insight on studies presented at the annual meeting of the American Society of Hematology.  Click here to read the full article.

Medscape Today: Brentuximab Shows “Amazing” Responses in Refractory Lymphoma

Wed, December 08, 2010

Medscape Today spoke with Dr. Andre Goy regarding a new experimental drug designed to fight Hodgkin's lymphoma.  Click here to read the full article.

Monthly Prescribing Reference: Carfilzomib Has Potential to Offer Substantial Clinical Benefit to Patients With Relapsed/Refract

Tue, December 07, 2010

Monthly Prescribing Reference covers Dr. David Siegel's study on Carfilzomib, in conjunction with the drug's producer Onyx Pharmaceuticals, Inc. Click here to read the full article.

Science Daily: Aggressive Blood Cancers: Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengra

Tue, December 07, 2010

Science Daily announces the John Theurer Cancer Center collaborated with the National Cancer Institute and the University of Pennsylvania on a clinical trial to evaluate the effectiveness of infusing cultured donor immune cells known as "T-rapa" cells after stem cell transplantation into patients being treated for blood-related cancers.  Click here to read the full article.

Science Daily: Aggressive Blood Cancers: Is Pralatrexate Effective in Patients With T-Cell Lymphoma Who Fail ICE-Based Regimens?

Tue, December 07, 2010

Science Daily reports on Dr. Andre Goy's study on Prlatrexate, presented at ASH 2010.  Click here to read the full article.

Science Daily: Aggressive Blood Cancer: Clinical Trial of Lenalidomide Plus Dexamethasone Followed by Autologous Stem Cell Trans

Tue, December 07, 2010

Science Daily reports on an abstract Dr. David Siegel developed with Onyx Pharmaceuticals Inc. as presented at the annual meeting of the American Society of Hematology (ASH).  Click here to read the full article.

Reuters Health: Early stem cell transplant still important for multiple myeloma

Tue, December 07, 2010

Reuters Health spotlights Dr. David Siegel's abstract on stem cell transplant for multiple myeloma patients, as presented at the annual meeting of the American Society of Hematology.  Click here to read the full article.

Xconomy: Onyx Unveils Results for Myeloma Drug, Raising Stakes in Rivalry with Millennium

Tue, December 07, 2010

Dr. David Siegel quoted on his collaboration with Onyx Pharmaceuticals for a study on experimental multiple myeloma drug Carfilzomib.  Click here to read the full article. 

Bloomberg: Onyx Drug Reduces Cancer in a Third of Patients with Deadly Blood Cancer

Tue, December 07, 2010

Dr. David Siegel highlighted for his involvement with the study on Onyx Pharmaceutical Inc.'s experimental drug Carfilzomib which is found to shrink tumors in one-third of study patients with multiple myeloma.  Read the full article here.